• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011-13).

作者信息

Mendes Rodrigo E, Castanheira Mariana, Farrell David J, Flamm Robert K, Sader Helio S, Jones Ronald N

机构信息

JMI Laboratories, North Liberty, IA, USA

JMI Laboratories, North Liberty, IA, USA.

出版信息

J Antimicrob Chemother. 2016 Jan;71(1):276-8. doi: 10.1093/jac/dkv303. Epub 2015 Oct 7.

DOI:10.1093/jac/dkv303
PMID:26451012
Abstract
摘要

相似文献

1
Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011-13).达巴万星对在美国和欧洲医院引起已记录皮肤及皮肤结构感染的革兰氏阳性临床分离株活性的最新研究（2011 - 2013年）
J Antimicrob Chemother. 2016 Jan;71(1):276-8. doi: 10.1093/jac/dkv303. Epub 2015 Oct 7.
2
Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-13).奥塔万星对欧洲和美国医院有记录的皮肤和软组织感染的革兰阳性临床分离株的活性（2010-2013 年）。
J Antimicrob Chemother. 2015 Feb;70(2):498-504. doi: 10.1093/jac/dku421. Epub 2014 Oct 31.
3
Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres.达巴万星对从美国和欧洲医疗中心的感染性心内膜炎患者中分离出的革兰阳性菌的抗菌活性研究。
J Antimicrob Chemother. 2019 May 1;74(5):1306-1310. doi: 10.1093/jac/dkz006.
4
In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections.达巴万星及其他12种药物对从糖尿病足感染中分离出的329株需氧和厌氧革兰氏阳性菌的体外活性。
Antimicrob Agents Chemother. 2006 Aug;50(8):2875-9. doi: 10.1128/AAC.00286-06.
5
Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections.达巴万星和奥利万星：治疗革兰氏阳性菌感染的创新方法。
Pharmacotherapy. 2015 Oct;35(10):935-48. doi: 10.1002/phar.1641.
6
Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol.达巴万星对来自欧洲和北美的临床分离株的抗菌谱及效力（2003年）：一项国际监测方案的初步结果
J Chemother. 2005 Dec;17(6):593-600. doi: 10.1179/joc.2005.17.6.593.
7
Microbiologic characterization of isolates from a dalbavancin clinical trial for catheter-related bloodstream infections.一项关于达巴万星治疗导管相关血流感染的临床试验中分离菌株的微生物学特征分析。
Diagn Microbiol Infect Dis. 2006 Feb;54(2):83-7. doi: 10.1016/j.diagmicrobio.2005.09.004.
8
Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens.达巴万星对部分耐抗菌药物革兰氏阳性病原体群体的活性。
Diagn Microbiol Infect Dis. 2005 Dec;53(4):307-10. doi: 10.1016/j.diagmicrobio.2005.03.004.
9
Longitudinal analysis of the in vitro activity profile of oritavancin and comparator glycopeptides against Gram-positive organisms from Europe: 2005-2008.2005 - 2008年奥利万星及对照糖肽类药物对欧洲革兰氏阳性菌体外活性谱的纵向分析
Int J Antimicrob Agents. 2010 Nov;36(5):474-6. doi: 10.1016/j.ijantimicag.2010.07.010. Epub 2010 Sep 16.
10
Dalbavancin: a new option for the treatment of gram-positive infections.达巴万星：治疗革兰氏阳性菌感染的新选择。
Ann Pharmacother. 2006 Mar;40(3):449-60. doi: 10.1345/aph.1G158. Epub 2006 Feb 28.

引用本文的文献

1
Proactive Therapeutic Drug MONiToring to Guide Suppressive Antibiotic Therapy with DALBAvaNcin ( > 12 weeks) in Osteoarticular Infections (MONTALBANO).前瞻性治疗药物监测以指导达巴万星（>12周）用于骨关节炎感染的抑制性抗生素治疗（MONTALBANO研究）
J Bone Jt Infect. 2025 Jul 30;10(4):255-263. doi: 10.5194/jbji-10-255-2025. eCollection 2025.
2
A systematic review of dalbavancin efficacy as a sequential therapy for infective endocarditis.达巴万星作为感染性心内膜炎序贯治疗药物疗效的系统评价。
Infection. 2025 Feb;53(1):15-23. doi: 10.1007/s15010-024-02393-9. Epub 2024 Sep 26.
3
New Evidence and Insights on Dalbavancin and Wound Healing in a Mouse Model of Skin Infection.
新证据和新见解：达巴万星在皮肤感染小鼠模型中的疗效和伤口愈合情况。
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.02062-19.
4
Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection.治疗革兰阳性皮肤和软组织感染、骨和关节感染的达巴万星真实世界经验。
Infection. 2019 Dec;47(6):1013-1020. doi: 10.1007/s15010-019-01354-x. Epub 2019 Sep 13.
5
Dalbavancin treatment of methicillin-susceptible Staphylococcus aureus pyomyositis with torpid evolution: a case report.达巴万星治疗进展缓慢的甲氧西林敏感金黄色葡萄球菌性脓性肌炎：一例报告
Rev Esp Quimioter. 2019 Jun;32(3):276-277. Epub 2019 Apr 30.
6
Comparative In Vitro Activities of New Antibiotics for the Treatment of Skin Infections.新型抗生素治疗皮肤感染的体外比较活性。
Clin Infect Dis. 2019 Apr 8;68(Suppl 3):S200-S205. doi: 10.1093/cid/ciz003.
7
Antimicrobial Activity of Dalbavancin against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from U.S. Medical Centers.美国医疗中心的耐糖肽类、达托霉素和/或利奈唑胺的低敏性金黄色葡萄球菌的达巴万星的抗菌活性。
Antimicrob Agents Chemother. 2018 Feb 23;62(3). doi: 10.1128/AAC.02397-17. Print 2018 Mar.
8
Single-Dose Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.单剂达巴万星：急性细菌性皮肤和皮肤结构感染的评价。
Drugs. 2017 Jan;77(1):75-83. doi: 10.1007/s40265-016-0666-0.
9
Dalbavancin for the treatment of paediatric infectious diseases.达巴万星用于治疗儿童感染性疾病。
Eur J Clin Microbiol Infect Dis. 2016 Dec;35(12):1895-1901. doi: 10.1007/s10096-016-2756-z. Epub 2016 Aug 25.